ASX ANNOUNCEMENT

Lumos Investor Presentation
Information Sessions and Webinar Reminder

MELBOURNE, Australia (27 July 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to release a copy of the presentation to be delivered by Chair, Sam Lanyon and CEO and Managing Director, Doug Ward during an investor roadshow through Melbourne and Sydney over the coming weeks.

Investor Webinar

The Company will be holding a webinar for shareholders and investors on Wednesday 29 July 2026 at 10:15am (AEST).

During the webinar briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert and Chief Commercial Officer, Paul Kase, will provide an overview of the quarterly results. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_nYvzMUPJQleS29qe_nqeCQ

Once the registration form is completed, participants will receive a confirmation email with details on how to access the webinar briefing.

In-Person Investor Briefing Sessions in Melbourne/Sydney

As part of the roadshow, Lumos will be holding investor briefing and Q+A sessions in Melbourne and Sydney. Details of the sessions are as follows:

To register, please email the address below, then enter your name and contact details.

Please register by close of business Tuesday, 28 July 2026.

Melbourne	**Wednesday, 29 July 2026, 3.15pm arrival for 3.30pm-4.30pm** William Buck, Level 20, 181 William Street, Melbourne. RSVP: ir@lumosdiagnostics.com - (specify Melbourne session)
Sydney	**Monday 3 August 2026, 3.00pm arrival for 3:15pm-4.15pm** Workspace 365 – Ruby Tuesday room Level 11, 66 Clarence Street, Sydney. RSVP: ir@lumosdiagnostics.com - (specify Sydney session)

The Lumos investor relations team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

Lumos Diagnostics Holdings Limited

Investor Presentation

27 July 2026

lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care.

Improving the practice of medicine.

Continuing to Deliver

First in Class Product FebriDx® Major U.S. Breakthrough Achieved

- US FDA CLIA waiver clearance granted on 27 March 2026
- CLIA waiver study exceeded performance targets (99%+ concordance)
- FebriDx® protected by a broad global patent estate covering method, device, and biomarkers

> US$1.0 Billion p.a. TAM for FebriDx

- CLIA waiver unlocks >80M ARI patient interactions annually in the US
- 0442U: proprietary PLA Code assigned for FebriDx®
- CMS established rate on CLFS (Clinical Lab Fee Schedule) for FebriDx at US$41.38 per test
- 100% Medicare reimbursement achieved across all 7 MACs. Private payor engagement commenced

Transformational US$317M (A$487M) Distribution Deal

- With PHASE Scientific for the US market over 6 years,[1] based on minimum order quantities (MOQ's) being achieved
- One of the largest POC distribution deals for an ASX-listed diagnostics company
- US$8.5m received to-date

Commercial Rollout Accelerating

- Initial commercial progress exceeding expectations.
- FebriDx being used in 170+ locations in ~3 months.
- Product is available in locations across 24 US states
- Data demonstrates >90% payer reimbursement, with claims paid at or above the Medicare benchmark of US$41.38 per test

Strong Balance Sheet, No Debt, No Royalties Payable

- Cash at bank of US$15.4m, no debt
- BARDA: US$6.2M non-dilutive funding (paediatric study)

Commercial Services Division

- Licensing/IP agreements add recurring high-margin revenue
- Hologic: US$10M IP licensing + US$7.7M development agreement for next-gen fFN women's health test
- Aptatek: Additional US$1.9M contract advancing in-home PKU monitoring
- Micro-Pak: 3-year manufacturing contract for Lumos developed, Mold Analyzer System

[1]AUD:USD of 0.651 as at 15 July 2025

Company Snapshot

Issued Capital	
Shares	944.4m
Options - Investors	86.8m
Options & Performance Rights - Employees	82.0m
Market Capitalization (AUD)	
Share price[1]	A$0.11
Market value	A$103.9m
Cash (30 June 2026 – in AUD)[2]	A$22.0m
Enterprise value	A$81.9m
Substantial shareholders	
Tenmile Ventures	19.8%
Ryder Capital	14.4%

Share Price & Volume

Board and Management

Sam Lanyon	Non-Executive Chairman
Doug Ward	CEO & Managing Director
Bronwyn Le Grice	Non-Executive Director
Lawrence Mehren	Non-Executive Director
Catherine Robson	Non-Executive Director
Barrie Lambert	Chief Financial Officer

[1]As at 24 July 2026
[2] Based on USD FX conversion rate of 0.70

Financials Summary – Quarterly

(Quarterly, US$ in thousands)

Revenue ($'000)



Revenue Mix



Net Cash Generation ($'000)*



Commentary

- **Revenue** of $2.3 million in Q4 FY26, down 14% on prior corresponding quarter Q4 FY25 (pcp). FY26 revenue was $13.2 million, up 6% yoy.
- **Products** revenue was $0.2 million in Q4 FY26, impacted by the timing of large orders received from PHASE in Q3 FY26 and the expected seasonally low trading period. FY26 revenue was $4.3 million, up 135% yoy. FebriDx® revenue was up 875% on yoy.
- **Services** revenue was $2.1 million in Q4 FY26, with 12 projects in progress. FY26 revenue was $8.9 million, down 16% yoy. Revenue was primarily affected by lower amortization rate of Hologic IP licence due to extension of project timeline. Project revenue was up 24%, excluding the IP line item.
- **Net cash inflow*** of $0.2 million in Q4 FY26, including $2.3 million of planned investment in facilities for manufacturing expansion.
- **Cash balance as at 30 June 2026** of $15.4 million. No debt.

**Net cash generation comprised of operating and investing cash flow, plus lease payments.*

FebriDx Updates

Investor News, Sales Events, Operations, Key Indicators, Paediatric Study, Marketing Plan

FebriDx® Investor News — May - July 2026

20 shareholder EDM updates across 15 key dates — FebriDx® commercialization, reimbursement, and market expansion



MOMENTUM: 170+ live U.S. sites, >90% payers reimbursed, Avg reimbursement >$41.38, and a BUY rating from MST, Foster Stockbroking, and Bell Potter.

FebriDx® Q2 CY2026 — key sales events

Lumos, Phase Scientific, AcuityMD, and PRO-spectus working in concert



MTMC Health Events: Attended 4 MTMC Customer Showcase Events in Q2

Facility expansion will underpin demand fulfillment at scale

Facility build-out on track for November 2026 completion to support market demand and drive revenue growth

Scale-up overview

- **Consolidation to a single 37k sq ft facility on-track for November 2026**
  - ready for 26/27 US flu season
- **>20k sq ft warehouse with temperature control;**
  - 20x increase from current facility
- **>6k sq ft new manufacturing lab space;**
  - 2x increase from current facility
- **$2.2m construction fees paid and included in FY26 accounts**
  - accounted for as capex on property, plant and equipment. Additional $0.5m required over 1H FY27
- **Capacity increased to accommodate foreseeable scale-up**

Facility

Commercial leading indicators dashboard

>170 sites

Live sites
(Standardized Adoption)

Expected slower ramp at low ARI season

>90% payment coverage @ >$41.48

Claim coverage and reimbursement value

Expected less coverage and value at launch

680k – 935k

Estimated number of ARI Visits covered

National average ARI per site per annum used

24

States with ordering sites

Significantly more than expected

Average ARI (acute respiratory illness) visits per US urgent care site: Sources: Urgent Care Association, Urgent Care Data (2025); Health Care Cost Institute, "Respiratory-Related Illness is the Top Reason People Use Urgent Care" (analysis of 73M commercial urgent care visits, 2018–2022).

Reporting Period: April–June 2026 | Data Sources: AcuityMD, PHASE Scientific, PRO-spectus, Distributor Tracings

FebriDx Paediatric Study Update

2-12 yrs
Paediatric age group under study

20% Increase
Total Available Market Expansion

250+
Patients enrolled (target ~500)

US$2.6M
Funding received so far

Study progress & milestones

Regulatory foundation

FebriDx® is FDA 510(k)-cleared and CLIA-waived for patients aged 12–64 with acute respiratory infection, enabling deployment across 300,000+ US point-of-care settings.

Market expansion

Success would extend FebriDx® eligibility to ~72% of the US population and support broader antibiotic stewardship for the 60,000 clinicians treating children aged 2–12.

Study Progression

US paediatric study commenced late 2025, evaluating FebriDx® in children aged 2–12 within CLIA-waived settings. ~12-month enrolment across a full respiratory season.

BARDA partnership

BARDA is funding the study with US$6.2M non-dilutive across 12 milestones (setup, enrolment, FDA submission, 510(k)/CLIA-waiver clearance) — strong external validation.

Note: US$ non-dilutive funding. Study outcomes subject to FDA review. Source: Lumos ASX announcement (23 Feb 2026), Lumos News (14 May 2026)

Our Marketing Partner for FebriDx®

CG Life is a purpose-built extension of the Lumos marketing team, experienced in the diagnostic space and ready to bring FebriDx® to the forefront of patient care.

A 175+ person team of scientists, artists, marketers, and communicators on a mission to help life sciences innovators turn scientific progress into better patient outcomes.

- Over 25 years of experience supporting complex technologies across applications
- Three core offices in San Diego, Chicago, New York, with satellite teams in major US bio hubs
- Fully integrated disciplines across:
  - PR & Strategic Communications
  - Research & Brand Development
  - Compelling Digital & Print Creative
  - Omnichannel Enablement & Activation

With a proven approach, point-of-care expertise, and commercial launch experience, they are built to deliver impact and results.

FY27 Priorities

Estimated US flu illnesses - by month

US flu season starts ramping up in November and runs from moderate-high through to end of March



Source: CDC, Flu Season (flu activity usually peaks between December and February); CDC, Influenza Activity in the United States during the 2024–25 Season (activity increased in mid-November and peaked in early February 2025); CDC, 2024–2025 Influenza Season Summary (51 million illnesses, 23 million medical visits).

Go-to-market plan: phased and focused

Phase 1
July – September

Discovery, Visibility, & Targeting

- Foundation documents: positioning, audience prioritization, messaging, and creative approach
- Audit and begin improving digital touchpoints
- CLIA waiver earned media activation to fuel demand across urgent care sites
- Thought leadership around clinical publications, AMR stewardship stories, and other narratives
- Tier 1 urgent care LinkedIn bridge campaign

Phase 2
October – December

Respiratory Surge

- Solidify and build off of shared strategic foundation
- Surge campaign: build momentum and scale as respiratory season continues
- Begin secondary audience outreach.
- Attend and amplify messaging trade shows.
- Case study content: Key Urgent Care Account + early adopter results published
- Begin sales enablement assets: rep toolkit, ROI calculators, objection guides

Phase 3
January – July 2027

Expansion & Demand

- Performance review + campaign optimization
- Retargeting media for warm leads from early phases to drive adoption and pique interest for next respiratory season
- Prepare for push at UCA 2027 (April)
- PR push with adoption.
- Completion of sales enablement materials

Q3 2026: Foundational Actions + Bridge Campaign → **Q4 2026:** Respiratory Season Surge + Asset Building → **1H 2027:** Continued Demand

Key Priorities

Drive sales & marketing plan to increase market awareness, expand clinical adoption, progress reimbursement coverage, and deliver on manufacturing scale-up to meet growing demand

Continue implementation of agreement with PHASE Scientific, in conjunction with our partnerships with Pro-spectus, AcuityMD and CG Life

Progress FebriDx paediatric study – fully funded with US$6.2M by BARDA - addresses important clinical market for 2 -12 yr olds and expands U.S. market by approx. 20%

Deliver on Hologic fFN development milestones - including the additional work statements from Phase 2 & Phase 3

Continue exploration of adjacent and other diagnostic tests product development opportunities

FebriDx® Opportunity

Novel proprietary point-of-care test for distinguishing between bacterial versus non-bacterial symptoms

The respiratory infection testing problem

Similar symptoms make it difficult to distinguish viral from bacterial infections, leading to precautionary antibiotic overprescription by doctors.

The respiratory infection testing problem…

The patient expectation is to find out what is wrong and they want answers quickly

+

Doctor's need certainty, but it is difficult to distinguish between viral and bacterial symptoms

Antibiotic overprescription

Doctors prescribe antibiotics to treat Acute Respiratory Infections (ARIs) in situations where it is unnecessary

Antibiotics are being overprescribed in the US

Antibiotics prescribed in the US by type[1]



58%
of all antibiotics prescribed may account for acute respiratory infection (ARI)[1]

1. **211 million** antibiotic prescriptions issued in outpatient settings each year[2]
2. **44%** of antibiotic prescriptions are written to treat patients with ARIs[3]
   - **40%** of these are unnecessary[4]

Source: (1) Centers for Disease Control and Prevention (2011). (2) Outpatient Antibiotic Prescriptions—United States 2021. (3) Unnecessary Antibiotics for Acute Respiratory Tract Infections: Associations with Care Setting and Patient Demographics (2016). (4) Tse, J.; Near, A. et al; Antibiotics (2022).

Our solution: FebriDx® | a simple microbial infection test

FebriDx® can rapidly identify patients who have a microbial infection[1] and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes

What is FebriDx®?

FebriDx® test procedure and interpretation of results



Patient can be treated with antibiotics

Viral infection – antibiotics will not work
Patient needs to be managed differently

What has it achieved?[2]

10min
to deliver a result leaves patients with actionable plan of trust

>99%
accuracy for ruling out bacterial infection

>90%
accuracy in differentiating viral vs. bacterial infection

Source: (1) Microbial infection is the invasion of infectious agents into the organism, their multiplication and the reaction of host tissue against these agents. Infectious agents include bacteria, virus, parasite and fungi. (2) Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting, Nathan I. Shapiro,MD, MPH, JAMA Network, 18 October 2022.

FebriDx® IP

Our FebriDx® licensing / IP agreements add recurring high-margin revenue



On-strip cell lysis

- Blood cell lysis chemical formulation
- Detection of intracellular and extracellular biomarkers

On-strip cell lysis

- CRP and MxA used in existing FebriDx product
- CRP and MxA precursors to block new entrants
- CRP, MxA and Procalcitonin to block new entrants and expand product offering
- CRP and alternate viral biomarkers to block new entrants
- MxA and alternate bacterial biomarkers to block new entrants

Lumos FebriDx Patents

- 59 FebriDx patents, 4 patent families
- 17 countries
- 50 granted, 9 pending
- Core MxA / CRP patent life in USA to 2038

Lumos Trademarks

- FebriDx is a registered trademark in the USA, EU and UK

CLIA waiver label expands our commercialisation options

It is clear that the two key US market opportunities for testing are in urgent care and primary care sites, these have formed our target sites as we continue commercialisation of FebriDx®

US market opportunities in acute respiratory infection testing[1]



2026 US market data demonstrates the opportunity

270k
CLIA Waived Locations

14k[2]
Urgent Care Locations

160k[3]
Primary Care Locations

174k
potential US urgent care and primary care sites

~68 million
ARI visits to US urgent care and primary care sites

Source: (1) Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid Services, March 2024 (CMS CLIA Data base). (2) Precision Business Insights, US Acute Respiratory Infections, 2024.(2) The Journal of Urgent Care Medicine, https://www.jucm.com/2024-urgent-cares-top-100-by-number-of-locations/. (3) CMS CLIA Database, March 2024 (Division of Clinical Laboratory Improvement and Quality, Centers for Medicare & Medicaid Services); U.S. urgent-care industry data; Precision Business Insights, 'US Acute Respiratory Infections', 2024. Estimated primary care site count (~160k) is a Lumos internal estimate derived from these data.

Commercial Strategy and Traction

Push + Pull + Prove Framework | Tier 1 Urgent Care Account Focus | Leading Indicators

Partner ecosystem accelerates commercial adoption

Lumos, Phase Scientific, AcuityMD, and PRO-spectus working in concert

Lumos Diagnostics
Product Owner & Manufacturer

- Product manufacturing & quality control
- IP protection and product compliance
- Marketing - education and awareness campaigns
- Strategic direction and regulatory oversight

PHASE Scientific
Exclusive 6-Year U.S. Distributor

- National exclusive distribution agreement with Tier 1 and Tier 2[1.] account focus
- Sub-distributor network deployment e.g. Henry Schein & McKesson
- Contract Sales Force (MTMC) training, implementation, and field execution
- Customer service and order management

AcuityMD
Claims Data Intelligence & Targeting

- Proprietary claims data identifies highest-value accounts
- Prioritizes pipeline by patient volume and payer mix
- Territory optimization and white-space analysis
- Weekly pipeline reviews with commercial team

PRO-spectus
Reimbursement Support Services

- Comprehensive reimbursement onboarding per site
- Payer mix review and billing workflow setup
- Claims tracking and denial management support
- Accelerates provider revenue confidence at go-live

1. Tier 1 refers to Top 50 Urgent Care group by number of sites. Tier 2 refers to 51-100.

FebriDx® - Three pillars of commercial adoption

All three pillars validated and in place; commercial readiness confirmed

#1 Clinical Benefit

- Only POC test distinguishing bacterial vs. non-bacterial ARI at triage
- 99% NPV to rule out bacterial infection (JAMA Network Open, 2022)
- Solution to unmet need. Patient satisfaction.
- Supports antibiotic stewardship - ~40% of ARI antibiotics unnecessary (CDC)

✓ Validated

#2 Economic Benefit

- Reimbursed via PLA code 0442U at $41.38/test (CMS 2025). Two years' process towards granting
- 100% Medicare MAC recognition — all U.S. regions achieved
- Private payor coverage expansion actively underway
- Sustainable margin for Lumos, distributors, and physicians

✓ Validated

#3 Operational Efficiency

- Instrument-free, CLIA-waived - zero capital equipment needed
- ~1-minute hands-on time; 10-minute result at triage
- Finger-prick integrates alongside COVID/Flu combo tests
- WellStreet standing order: result before doctor sees patient in exam room

✓ Validated

FebriDx® US commercialization strategy

Push + Pull + Prove: focused resources, targeted demand creation, disciplined measurement

Push

Focus Sales Resources

- Account teams on Tier 1 and 2 high-value urgent care chains
- Phase Scientific: Sub Distributor network & Contract Sales representation (MTMC Health)
- Used WellStreet model to create the playbook for standardising site onboarding and incorporates PRO-spectus support (reimbursement readiness)
- AcuityMD claims data targeting & prioritisation

Pull

Create Awareness & Demand

- KOL engagement at Tier 1 priority accounts
- Digital campaigns targeting urgent care operators
- Peer-proof case studies and real-world evidence
- Marketing agency selected to support drive from awareness to adoption

Prove

Measure & Adjust Fast

- Pull-through dashboard: site-level utilization tracking via monthly distributor tracings
- Individual physician adoption via claims reporting
- Reimbursement metrics: paid claims & denial rates
- AcuityMD CRM tracks pipeline conversion weekly

Market concentration matters

Top 100 operators control 40% of urgent care sites



Source: Journal of Urgent Care Medicine, 1 April 2025

Top 50 Urgent Care Groups — Tier 1

Ranked by total U.S. sites | Source: Journal of Urgent Care Medicine 2025 | Hospital affiliation count shown in teal where applicable

#	Corporate Entity	Sites	Hosp. Aff.	HQ City / State
1	**American Family Care**	403	17	Birmingham, AL
2	**HCA Healthcare**	333	333	Nashville, TN
3	**GoHealth Urgent Care**	307	307	Atlanta, GA
4	**Fast Pace Health**	301	—	Waynesboro, TN
5	**CityMD Urgent Care**	190	—	New York, NY
6	**WellNow Urgent Care**	165	24	Chicago, IL
7	**NextCare Urgent Care**	145	41	Tempe, AZ
8	**WellStreet Urgent Care**	145	145	Atlanta, GA
9	**Advocate Health**	119	119	Charlotte, NC
10	**Community Care Partners**	107	—	Eugene, OR
11	University of Pittsburgh Medical Center	107	107	Pittsburgh, PA
12	Carbon Health Urgent Care	96	—	San Francisco, CA
13	CRH Healthcare	95	78	Atlanta, GA
14	PM Pediatrics	85	15	New Hyde Park, NY
15	Urgent Team	85	—	Nashville, TN
16	CommonSpirit Health	82	82	Chicago, IL
17	Patient First	79	—	Glen Allen, VA
18	Providence Health & Services	74	74	Renton, WA
19	Premier Health	68	68	Dayton, OH
20	Xpress Wellness	68	—	Oklahoma City, OK
21	Sanford Health	68	68	Sioux Falls, SD
22	Bon Secours Mercy Health	65	65	Blue Ash, OH
23	Access Medical Clinic	63	—	Jonesboro, AR
24	Novant Health	62	62	Winston-Salem, NC
25	Trinity Health	61	61	Livonia, MI

#	Corporate Entity	Sites	Hosp. Aff.	HQ City / State
26	Exer – More Than Urgent Care	61	—	Calabasas, CA
27	MainStreet Family Urgent Care	61	—	Birmingham, AL
28	UrgentCare Group	59	11	Nashville, TN
29	AdventHealth Centra Care	57	57	Maitland, FL
30	Midwest Express Clinic	53	—	Willowbrook, IL
31	FastMed Urgent Care	52	—	Raleigh, NC
32	MultiCare Health System	52	52	Tacoma, WA
33	Banner Health	48	48	Phoenix, AZ
34	CareSpot Urgent Care	46	34	Jacksonville, FL
35	Community Health Systems	46	46	Franklin, TN
36	Next Level Urgent Care	46	—	Houston, TX
37	ConvenientMD	45	—	Portsmouth, NH
38	Ardent Health Services	43	43	Brentwood, TN
39	CareFirst Urgent Care	42	—	Cincinnati, OH
40	Cleveland Clinic	42	42	Cleveland, OH
41	Rock Oak Capital	42	—	Machesney Park, IL
42	OSF HealthCare	41	41	Peoria, IL
43	AllCare Family Medicine & Urgent Care	40	—	Alexandria, VA
44	Sutter Health	40	40	Sacramento, CA
45	Endeavor Health	39	—	Evanston, IL
46	PeaceHealth ZoomCare	38	38	Tigard, OR
47	Intermountain Health	38	38	Salt Lake City, UT
48	My Dr Now	38	—	Chandler, AZ
49	Ascension Health	36	36	St. Louis, MO
50	Ochsner Rush Health	35	—	Meridian, MS

4,548
Tier 1 Total Sites
79% of all Top-100 sites

403→35
Site Range (Top 50)
American Family Care → Ochsner

62%
Hospital-Affiliated Groups
31 of 50 groups

23
U.S. States Represented
Tier 1 HQ locations

#1
Reason for Urgent Care Visits
Respiratory illness (HCCI 2024)

 | *Sources: Journal of Urgent Care Medicine 2025; Experity Health 2026; JHEOR FebriDx Economic Evaluation 2021; Health Care Cost Institute 2024*

FebriDx® US Focus: Standardized Adoption

PIPELINE FUNNEL



STAGE DEFINITIONS

Qualified Opportunities
Priority accounts identified and engaged based on patient volume, payer mix, strategic fit and network scale.

Clinical & Economic Validation
Account purchases FebriDx to validate clinical performance, reimbursement, workflow and health-economic assessment conducted across one or more locations to support broader adoption decisions.

Network Rollout
Deployment across multiple sites within an account following successful validation of clinical utility, operational fit and reimbursement.

Standardized Adoption
FebriDx becomes embedded in standing orders, triage protocols or routine clinical pathways, supporting repeat ordering and scaled utilisation across the account.

FebriDx® US Focus: Account Strategy

PIPELINE FUNNEL



PRIORITY FOCUS: TOP 100 URGENT CARE GROUPS

Urgent Care Ownership Groups – 400

- Health system affiliated - 58%
- PE-backed – 29%
- Independent – 13%
- Total Urgent Care Sites – 14,442

Top 100 Ownership Group Facts:

- **Sites**: 5,722 sites (40% of total urgent care sites)
- **ARI related visits**[1]: 22.9 million - 31.5 million
- **Flu tests performed**[2]: 5.7 million - 8.5 million

1. *Average ARI (acute respiratory illness) visits per US urgent care site: ~4,000–5,500 per year (~12–17 per day)Derived from: UCA average visit volume of ~34 patients/day/site (2025), annualized to ~12,400 visits/site/year, multiplied by respiratory-related illness share of ~35–40% of urgent care visits (the single largest visit category).Sources: Urgent Care Association, Urgent Care Data (2025); Health Care Cost Institute, "Respiratory-Related Illness is the Top Reason People Use Urgent Care" (analysis of 73M commercial urgent care visits, 2018–2022).*

2. *Average Flu Source from PBI 2025.*

FebriDx® US Focus: Commercial Status

PIPELINE FUNNEL



COMMERCIAL PROGRESS

Evaluation Phase: Key Highlights

- 350+ sites currently undergoing clinical and economic validation
- Includes accounts in Top 10, Top 25 & Top 30
- 1.4m to 1.9m estimated ARI visits per annum

Implementation Phase: Key Highlights

- 170+ live sites across 24 states
- Includes 2x Top 100 accounts
- 680k to 935k estimated ARI visits per annum

Top 100 Case Study: another urgent care group progressing

Validation underway across a second regional health system — supporting potential pathway to broader network adoption

Top 100 Urgent Care (>25 sites)

- One of the southeast's largest not-for-profit, integrated healthcare systems. A network of more than 400 care locations, supported by over 35,000 team members and one of the region's largest physician networks
- The health system operates more than 25 urgent care sites, creating a meaningful future deployment opportunity if validation outcomes are successful
- Urgent care sites provides a high-volume setting for ARI triage, antibiotic stewardship and standardised workflow assessment
- The system's footprint also spans >10 hospitals, >300 medical office locations, delivering comprehensive care from prevention and wellness through acute and specialty services
- Successful validation in the urgent care sites may support expansion into broader ambulatory settings across an integrated health system channel

Urgent Care Sites

>25 Sites

Clinical & Economic Validation

Clinical performance, reimbursement dynamics, workflow fit and health-economic impact are being assessed across select locations.

Estimated ARI visits per year: 100K – 138K across >25 sites

Reimbursement is working

PLA code 0442U is performing above benchmark - reimbursement traction validated in the field

>90%

Claims Paid

Paid claim rate on submitted FebriDx tests

Above Benchmark

>90% payment coverage @ >$41.48

Medicare Benchmark

PLA code 0442U (CMS 2025 clinical lab fee schedule)

Expected less coverage and value at launch

Unlocking commercial opportunity

- Claims paid >90% - providers receive consistent reimbursement at launch
- 100% Medicare MAC recognition across all U.S. regions — no geographic gaps
- Private payor payment on average >$41.38, allows sustainable provider margin
- Sustainable margin key to unlocking commercial opportunity

Commercial Services Division

How we add value to partners

We work with partners through the whole diagnostic product development cycle, then provide support once their products are in market.



Commercial Services - Partnership Examples

Hologic – Fetal Fibronectin (fFN)

- **fFN** is a biomarker indicating a heightened risk of pre-term delivery and is the largest segment of the pre-term birth diagnostic kit market
- **Project** - Development of an improved version of one of Hologic's leading in-market women's health products, Fetal Fibronectin (fFN), including adapting it for use on Lumos' proprietary reader platform.
- **Agreement** signed January 2024. Currently valued at between US$17.0m – US$17.7m, has two components:
  - IP: US$10.0m
  - Development: US$7.0m – US$7.7m
- US$14.4 million received to date
- **Timeline** – completion expected by June 2028
- **Future Opportunity** – validation and verification, clinical study, manufacturing, additional products

Aptatek – PKU in-home monitoring

- **PKU** affects 1 in 12,000 newborns, leading to neurological complications if un-checked
- **Agreement** follow-on contracts valued at $2.2M to complete development, verification studies and clinical validation of the PKU in-home monitoring device. Contract commenced September 2025, to be charged on time-and-materials basis.
- **Project** - Lumos activities:
  - Maturing the design of the test and blood processing unit
  - Finalising customisation of the Lumos digital reader
  - Formal verification testing to ensure the device meets product requirements for clinical trials and FDA submission
  - IRB approved multi-centre clinical study to advance to FDA submission
- **Future Opportunity** - PheCheck™ test and reader manufacturing, additional products

Micro-Pak – Mold Analyzer System

- **Mold Analyzer System** enables rapid on-site detection of mould for professional and consumer use, reducing turnaround times versus lab-based analysis
- **Background** developed by Lumos over the last four years for Micro-Pak and comprises a novel mould detection test, Lumos digital camera reader, and a custom mobile application
- **New Agreement** is a follow-on contract for the Lumos Commercial Services Division which covers the production of custom readers and point-of-care tests
- **Purchase Order** – First purchase order received April 2026 under the agreement, valued at US$0.3M and second PO for $0.2m in July. This new contract manufacturing agreement is for three years, with auto one year renewal periods
- **Future Opportunity** – additional products

Thank You

Lumos Diagnostics Holdings Limited | ASX: LDX

ir@lumosdiagnostics.com · lumosdiagnostics.com

This presentation contains forward-looking statements. Past performance is not necessarily indicative of future results.